KNSA — Kiniksa Pharmaceuticals International, plc stock price, charts and financials
QT79Kiniksa Pharmaceuticals International, plcKiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) is a Healthcare company in the Medical - Pharmaceuticals industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
76.85
+0.79+1.04%
TA
Loading chart...
Snapshot
| Index | - | P/E | 71.08 | EPS (ttm) | 1.07 | Insider Own | 5.87% | Shs Outstand | 76.21M | Perf Week | 2.31% |
| Market Cap | 5.80B | Forward P/E | 37.07 | EPS next Y | 2.05 | Insider Trans | -16.35% | Shs Float | 72.86M | Perf Month | 16.34% |
| Enterprise Value | 5.63B | PEG | 0.04 | EPS next Q | 0.36 | Inst Own | - | Short Float | 6.19% | Perf Quarter | 33.60% |
| Income | 79.41M | P/S | 6.89 | EPS this Y | 42.12% | Inst Trans | - | Short Ratio | 5.53 | Perf Half Y | 78.63% |
| Sales | 840.85M | P/B | 9.02 | EPS next Y | 47.30% | ROA | 9.00% | Short Interest | 4.51M | Perf YTD | 84.39% |
| Book/sh | - | P/C | 31.86 | EPS next 5Y | 45.60% | ROE | 13.65% | 52W High | 83.80 -8.30% | Perf Year | 132.46% |
| Cash/sh | - | P/FCF | 31.66 | EPS past 3/5Y | -33.93% - | ROIC | 9.71% | 52W Low | 32.11 139.33% | Perf 3Y | 300.32% |
| Dividend Est. | - | EV/EBITDA | 50.22 | Sales past 3/5Y | 45.52% - | Gross Margin | 54.49% | Volatility | 4.08% 4.89% | Perf 5Y | 396.15% |
| Dividend TTM | - | EV/Sales | 6.69 | EPS Y/Y TTM | 263.33% | Oper. Margin | 11.92% | ATR (14) | 3.49 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 3.49 | Sales Y/Y TTM | 98.82% | Profit Margin | 9.59% | RSI (14) | 63.28 | Recom | 2.00 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.90 | EPS Q/Q | 30.43% | SMA20 | 10.18% | Beta | 0.09 | Target Price | 86.40 |
| Payout | 0.00% | Debt/Eq | 0.01 | Sales Q/Q | 55.41% | SMA50 | 24.51% | Rel Volume | 0.29 | Prev Close | 76.06 |
| Employees | 366 | LT Debt/Eq | 0.01 | Earnings | Oct 27 | SMA200 | 55.51% | Avg Volume | 755.90K | Price | 76.85 |
| IPO Date | May 24, 2018 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 0.18% 7.56% | Net Debt/EBITDA | -1.49 | Volume | 219,775 | Change | 1.04% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-30-26 | Reiterated | Goldman Sachs | Buy | $75 → $90 |
| Jul-29-26 | Reiterated | Canaccord Genuity | Buy | $62 → $98 |
| Jul-29-26 | Reiterated | Wedbush | Outperform | $72 → $99 |
| Jul-23-26 | Reiterated | Goldman Sachs | Buy | $55 → $75 |
| Jul-13-26 | Reiterated | Wells Fargo | Overweight | $34 → $74 |
| Jun-29-26 | Reiterated | Wedbush | Outperform | $59 → $72 |
| Apr-29-26 | Reiterated | Wedbush | Outperform | $58 → $59 |
| Apr-28-26 | Reiterated | Jefferies | Buy | $54 → $71 |
| Apr-16-26 | Reiterated | Wedbush | Outperform | $50 → $58 |
| Feb-19-26 | Initiated | Canaccord | Buy | $62 |
Latest News
Aug-07-26
Aug-07-2604:01PM
Aug-03-26
Jul-31-26
Jul-31-2607:36PM
Jul-30-26
Jul-30-2601:21PM
Jul-28-26
10:23AM
10:05AM
07:30AM
Jul-23-26
Jul-22-26
Jul-22-2609:56AM
Jul-21-26
Jul-21-2610:50AM
Jul-15-26
Jul-15-2611:08AM
Jul-14-26
Jul-13-26
Jul-13-2608:05AM
Company
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 841 | 678 | 423 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 383 | 307 | 61 | — | — | — | — | — | — | |
| Gross Profit | 458 | 370 | 362 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 231 | 196 | 168 | — | — | — | — | — | — | |
| Research and Development | 127 | 97 | 112 | — | — | — | — | — | — | |
| Other Operating Expense | 0 | 0 | 128 | — | — | — | — | — | — | |
| Operating Income | 100 | 77 | -46 | — | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 14 | 12 | 9 | — | — | — | — | — | — | |
| Net Income Before Taxes | 114 | 89 | -36 | — | — | — | — | — | — | |
| Income Taxes | 34 | 30 | 7 | — | — | — | — | — | — | |
| Consolidated Net Income | 80 | 59 | -43 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 80 | 59 | -43 | — | — | — | — | — | — | |
| Net Income | 80 | 59 | -43 | — | — | — | — | — | — | |
| EPS (Recurring) | 1.07 | 0.80 | -0.60 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 1.07 | 0.80 | -0.60 | — | — | — | — | — | — | |
| EPS (Diluted) | 0.98 | 0.75 | -0.60 | — | — | — | — | — | — | |
| EBITDA | 113 | 90 | -34 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 78.42 | 55.00 | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 7.13 | 4.50 | 3.32 | — | — | — | — | — | — | |
| Gross Margin | 54.46 | 54.57 | 85.58 | — | — | — | — | — | — | |
| Operating Margin | 11.89 | 11.36 | -10.87 | — | — | — | — | — | — | |
| Net Margin | 9.51 | 8.70 | -10.17 | — | — | — | — | — | — | |
| Shares Outstanding | 78 | 74 | 71 | — | — | — | — | — | — | |
| Market Capitalization | 5,994 | 3,053 | 1,404 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Levy Richard S | Director | Aug 01 '26 | Option Exercise | 0.00 | 403 | 0 | 22,359 | Aug 04 |
| Cole G Bradley | Director | Jul 29 '26 | Sale | 81.43 | 3,673 | 299,092 | 11,672 | Jul 31 |
| Popovits Kimberly J | Director | May 29 '26 | Option Exercise | 0.00 | 2,799 | 0 | 15,345 | Jun 02 |
| Quart Barry D | Director | May 29 '26 | Option Exercise | 0.00 | 2,799 | 0 | 15,345 | Jun 02 |
| McCain Tracey L | Director | May 29 '26 | Option Exercise | 0.00 | 2,799 | 0 | 15,345 | Jun 02 |
| Malley Thomas | Director | May 29 '26 | Option Exercise | 0.00 | 2,799 | 0 | 15,345 | Jun 02 |
| Levy Richard S | Director | May 29 '26 | Option Exercise | 0.00 | 2,799 | 0 | 21,956 | Jun 02 |
| Cole G Bradley | Director | May 29 '26 | Option Exercise | 0.00 | 2,799 | 0 | 15,345 | Jun 02 |
| Paolini John F. | CHIEF MEDICAL OFFICER | May 01 '26 | Sale | 53.71 | 58,424 | 3,137,823 | 65,623 | May 05 |
| Paolini John F. | CHIEF MEDICAL OFFICER | May 01 '26 | Option Exercise | 10.36 | 58,424 | 605,273 | 124,047 | May 05 |
| Patel Sanj K | CHAIRMAN & CEO | May 01 '26 | Sale | 54.02 | 48,565 | 2,623,481 | 0 | May 01 |
| Patel Sanj K | CHAIRMAN & CEO | May 01 '26 | Option Exercise | 30.93 | 48,565 | 1,502,115 | 48,565 | May 01 |
| Patel Sanj K | CHAIRMAN & CEO | Apr 30 '26 | Sale | 54.01 | 2,141 | 115,635 | 0 | Apr 30 |
| Patel Sanj K | CHAIRMAN & CEO | Apr 30 '26 | Option Exercise | 30.93 | 2,141 | 66,221 | 2,141 | Apr 30 |
| Patel Sanj K | CHAIRMAN & CEO | Apr 29 '26 | Option Exercise | 30.93 | 22,544 | 697,286 | 22,544 | Apr 30 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.